LUNG CANCER REMAINS THE LEADING CAUSE OF CANCER RELATED DEATH IN THE UNITED STATES. AS MEDICAL EXPERT DOCTOR RAMO EXPLAINS, RECENT GUIDELINE CHANGES COULD HELP SAVE THOUSANDS OF LIVES. LUNG CANCER IS ...

The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...

The U.S. Food and Drug Administration (FDA) on Tuesday approved Insmed Incorporated’s (NASDAQ:INSM) Brinsupri (brensocatib 10 ...

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

A first-in-class reversible dipeptidyl peptidase-1 (DPP-1) inhibitor, brensocatib addresses the underlying inflammatory ...

The air we breathe is getting worse here in the Lehigh Valley, according to the American Lung Association's State of the Air report.

Brinsupri is the first approved therapy to address the underlying inflammatory process of non-cystic fibrosis bronchiectasis ...

An air quality alert was reported by the National Weather Service on Tuesday at 12:17 p.m. in effect until 8 p.m. for ...

The diagnosis of chronic obstructive pulmonary disease, or COPD, is improved by incorporating CT lung imaging and respiratory ...

Researchers have found a promising treatment breakthrough for chronic obstructive pulmonary disease (COPD) that avoids many ...

With more than 55 million children and 6 million adults spending their days in K–12 school buildings across the country, the American Lung Association is urging school administrators to prioritize ...

Brensocatib (Brinsupri; Insmed) gains FDA approval as the first treatment for bronchiectasis, offering hope to patients with ...